• Je něco špatně v tomto záznamu ?

Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis

AD. Lake, AL. Chaput, P. Novak, NJ. Cherrington, CL. Smith,

. 2016 ; 122 (-) : 62-71. [pub] 20161109

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023508

The molecular mechanisms behind the transition from simple steatosis to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) are not clearly understood. This hinders development of effective therapies for treatment and prevention of NASH. In this study expression profiling data from normal, steatosis, and NASH human livers were used to predict transcription factors that are misregulated as mechanistic features of NAFLD progression. Previously-published human NAFLD gene expression profiling data from normal, steatosis, and NASH livers were subjected to transcription factor binding site enrichment analysis. Selected transcription factors that bind enriched transcription factor binding sites were analyzed for changes in expression. Distinct transcription factor binding sites were enriched in genes significantly up- or down-regulated in NASH livers. Those enriched in up-regulated genes were bound by transcription factors such as FOXA, CEBP, and HNF1 family members, while those enriched in down-regulated genes were bound by nuclear receptors involved in xenobiotic sensing and lipid metabolism. Levels of mRNA and protein for selected transcription factors were significantly changed during disease progression. The study indicates that NAFLD progression involves changes in activity or expression of transcription factors that regulate genes involved in hepatic processes known to be altered in NASH. Transcription factors such as PPAR receptors, FoxA family members, and HNF4A might be targeted therapeutically to prevent NAFLD progression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023508
003      
CZ-PrNML
005      
20170720123533.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2016.11.006 $2 doi
035    __
$a (PubMed)27836672
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lake, April D $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
245    10
$a Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis / $c AD. Lake, AL. Chaput, P. Novak, NJ. Cherrington, CL. Smith,
520    9_
$a The molecular mechanisms behind the transition from simple steatosis to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) are not clearly understood. This hinders development of effective therapies for treatment and prevention of NASH. In this study expression profiling data from normal, steatosis, and NASH human livers were used to predict transcription factors that are misregulated as mechanistic features of NAFLD progression. Previously-published human NAFLD gene expression profiling data from normal, steatosis, and NASH livers were subjected to transcription factor binding site enrichment analysis. Selected transcription factors that bind enriched transcription factor binding sites were analyzed for changes in expression. Distinct transcription factor binding sites were enriched in genes significantly up- or down-regulated in NASH livers. Those enriched in up-regulated genes were bound by transcription factors such as FOXA, CEBP, and HNF1 family members, while those enriched in down-regulated genes were bound by nuclear receptors involved in xenobiotic sensing and lipid metabolism. Levels of mRNA and protein for selected transcription factors were significantly changed during disease progression. The study indicates that NAFLD progression involves changes in activity or expression of transcription factors that regulate genes involved in hepatic processes known to be altered in NASH. Transcription factors such as PPAR receptors, FoxA family members, and HNF4A might be targeted therapeutically to prevent NAFLD progression.
650    _2
$a vazebná místa $7 D001665
650    _2
$a progrese nemoci $7 D018450
650    _2
$a down regulace $7 D015536
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese $x fyziologie $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a nealkoholová steatóza jater $x metabolismus $7 D065626
650    _2
$a vazba proteinů $7 D011485
650    _2
$a transkripční faktory $x metabolismus $7 D014157
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chaput, Alexandria L $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
700    1_
$a Novak, Petr $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States; Biology Centre ASCR, Institute of Plant Molecular Biology, Branisovska 31, Ceske Budejovice CZ-37005, Czech Republic.
700    1_
$a Cherrington, Nathan J $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
700    1_
$a Smith, Catharine L $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States. Electronic address: csmith@pharmacy.arizona.edu.
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 122, č. - (2016), s. 62-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27836672 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124026 $b ABA008
999    __
$a ok $b bmc $g 1239189 $s 984421
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 122 $c - $d 62-71 $e 20161109 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...